ImmuPharma plc (LON:IMM – Get Free Report) was up 8.7% during mid-day trading on Monday . The stock traded as high as GBX 4.95 ($0.06) and last traded at GBX 4.28 ($0.05). Approximately 20,002,631 shares traded hands during trading, an increase of 2% from the average daily volume of 19,701,029 shares. The stock had previously closed at GBX 3.94 ($0.05).
ImmuPharma Stock Performance
The company has a market capitalization of £19.42 million, a price-to-earnings ratio of -466.40 and a beta of 1.53. The business’s 50-day simple moving average is GBX 1.75 and its 200-day simple moving average is GBX 1.73.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Investing In Preferred Stock vs. Common Stock
- MP Materials: Rare Earth Elements Powering the EV Boom
- Ride Out The Recession With These Dividend Kings
- Verizon’s Turnaround Gains Traction: New Highs Are Likely in 2025
- What Are Dividend Challengers?
- Bloom Energy: Powering the Future With Decentralized Energy
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
